The CDR1 peptide SCTGTSSDVGGYNYVSWYQ (homologous to IGLV2-11*03) was identified first as a potential biomarker candidate in primary open-angle glaucoma (POAG) patients [27] and offers promising properties as a therapeutic agent. Here, IGLV2-11 is linked to open-angle glaucoma.